tiprankstipranks
Burning Rock Biotech Ltd. (BNR)
NASDAQ:BNR

Burning Rock Biotech (BNR) Stock Price & Analysis

77 Followers

BNR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.29 - $21.90
Previous Close$6.5
Volume1.62K
Average Volume (3M)6.50K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)¥615.10M
Total Debt (Recent Filing)¥12.32M
Price to Earnings (P/E)
Beta1.59
Aug 28, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.02
Shares Outstanding10,258,726
10 Day Avg. Volume4,328
30 Day Avg. Volume6,502
Standard Deviation0.20
R-Squared0.00214
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.09
Price to Sales (P/S)0.10
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

0.00%47.74%0.68%51.57%
0.00%
Insiders
0.68% Other Institutional Investors
51.57% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

BNR FAQ

What was Burning Rock Biotech Ltd.’s price range in the past 12 months?
Burning Rock Biotech Ltd. lowest stock price was $5.29 and its highest was $21.90 in the past 12 months.
    What is Burning Rock Biotech Ltd.’s market cap?
    Currently, no data Available
    When is Burning Rock Biotech Ltd.’s upcoming earnings report date?
    Burning Rock Biotech Ltd.’s upcoming earnings report date is Aug 28, 2024 which is in 37 days.
      How were Burning Rock Biotech Ltd.’s earnings last quarter?
      Burning Rock Biotech Ltd. released its earnings results on May 29, 2024. The company reported -$0.249 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.249.
        Is Burning Rock Biotech Ltd. overvalued?
        According to Wall Street analysts Burning Rock Biotech Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Burning Rock Biotech Ltd. pay dividends?
          Burning Rock Biotech Ltd. does not currently pay dividends.
          What is Burning Rock Biotech Ltd.’s EPS estimate?
          Burning Rock Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Burning Rock Biotech Ltd. have?
          Burning Rock Biotech Ltd. has 8,232,740 shares outstanding.
            What happened to Burning Rock Biotech Ltd.’s price movement after its last earnings report?
            Burning Rock Biotech Ltd. reported an EPS of -$0.249 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Burning Rock Biotech Ltd.?
              Among the largest hedge funds holding Burning Rock Biotech Ltd.’s share is Bridgewater Associates, LP. It holds Burning Rock Biotech Ltd.’s shares valued at N/A.
                ---

                Burning Rock Biotech Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -69.33%
                12-Months-Change

                Fundamentals

                Return on Equity
                -65.40%
                Trailing 12-Months
                Asset Growth
                -33.93%
                Trailing 12-Months

                Company Description

                Burning Rock Biotech Ltd.

                Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and LungPlasma. The company has developed various cancer detection products , involving tumor targeting, oncomitant diagnosis of immune drugs, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress and detection of tumor sensitivity.
                ---

                BNR Company Deck

                ---

                BNR Earnings Call

                Q1 2024
                0:00 / 0:00
                ---

                BNR Stock 12 Month Forecast

                Average Price Target

                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","15":"$15","23":"$23","31":"$31","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,7,15,23,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Nov<br/>2023","25":"Nov<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,9.046153846153846,8.292307692307693,7.538461538461538,6.784615384615385,6.030769230769231,5.276923076923077,4.523076923076923,3.769230769230769,3.0153846153846153,2.2615384615384615,1.5076923076923077,0.7538461538461529,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,9.046153846153846,8.292307692307693,7.538461538461538,6.784615384615385,6.030769230769231,5.276923076923077,4.523076923076923,3.769230769230769,3.0153846153846153,2.2615384615384615,1.5076923076923077,0.7538461538461529,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,9.046153846153846,8.292307692307693,7.538461538461538,6.784615384615385,6.030769230769231,5.276923076923077,4.523076923076923,3.769230769230769,3.0153846153846153,2.2615384615384615,1.5076923076923077,0.7538461538461529,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.6,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.5,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29.3,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29.1,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.1,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.9,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.8,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.5,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.9,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.7,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.7,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                BioNano Genomics
                Bioxcel Therapeutics
                Bluebird Bio
                BioCryst

                Best Analysts Covering BNR

                1 Year
                David LiBank of America Securities
                1 Year Success Rate
                0/4 ratings generated profit
                0%
                1 Year Average Return
                -64.30%
                reiterated a buy rating 11 months ago
                Copying David Li's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -64.30% per trade.
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis